SCHEMBL502056

SCHEMBL502056

Cc1cc2c(cn1)cc(-c1cc(C(N)=O)ccc1C)c(=O)n2C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.54
ABL1 P00519 1/20 0.42
FGFR1 P11362 3/20 0.41
SRC P12931 3/20 0.41
KDM4E B2RXH2 1/20 0.40
BRD4 O60885 1/20 0.40
ALDH1A1 P00352 1/20 0.40
BRPF1 P55201 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
AR P10275 2/20 0.39
MAPKAPK2 P49137 2/20 0.38
MAPK13 O15264 1/20 0.38
RAF1 P04049 1/20 0.38
PDGFRA P16234 1/20 0.38
MAPK12 P53778 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPK11 Q15759 1/20 0.38
LCK P06239 2/20 0.38
KIT P10721 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502525 0.89 MAPK14 (0.53) MAPK14FGFR1SRCKDM4EALDH1A1
SCHEMBL502658 0.86 MAPK14 (0.42) MAPK14FGFR1SRCMAPKAPK2MAPK13
SCHEMBL501861 0.84 MAPK14 (0.40) MAPK14FGFR1SRCMAPKAPK2MAPK13
SCHEMBL502548 0.83 SRC (0.47) MAPK14ABL1FGFR1SRCALDH1A1
SCHEMBL10043916 0.82 MAPK14 (0.47) MAPK14KDM4EALDH1A1MAPKAPK2MAPK13
SCHEMBL10043901 0.82 KCNQ3 (0.49) MAPK14ABL1MAPKAPK2MAPK13RAF1
SCHEMBL10043705 0.81 MAPT (0.54) MAPK14ABL1KDM4EALDH1A1SMN1; SMN2
SCHEMBL10043925 0.80 MAPK14 (0.47) MAPK14MAPKAPK2MAPK13RAF1PDGFRA
SCHEMBL10043926 0.80 MAPK14 (0.45) MAPK14ABL1ALDH1A1MAPKAPK2MAPK13
SCHEMBL10043922 0.80 MAPK14 (0.48) MAPK14ABL1ALDH1A1SMN1; SMN2MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
CN-101528744-A Compositions and methods for modulating C-KIT and PDGFR receptors IRM LLC (VG) 2009-09-09 CN disclosed
EP-2076513-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2009-07-08 EP disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed
WO-2008051757-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-05-02 WO disclosed
WO-2008051757-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPK14 117/4885ABL1 59/4885FGFR1 34/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPK14 117/4885ABL1 59/4885FGFR1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.